The Fisher lab has a long collaborative history with the Johns Hopkins Brady Urological Institute's (JHBUI) Biorepository. The vision of the current Biorepository began in 1994, when Dr. Alan Partin initiated patient consent under an approved IRB for the first patient for a prostate cancer biomarker study. Patient enrollment in biomarker studies has continued throughout the past 15 years and current collection totals include 13,500 participating patients; totaling over 150,000 individual sample aliquots available for research purposes.
The JHBUI has evolved to include additional departmental bio-banking protocols. Patients visiting the Johns Hopkins Hospital Outpatient Center for the treatment or risk of prostate cancer, bladder cancer, and kidney cancer, are invited to participate in biorepository study. Sample donations from enrolled patients include plasma, cellular buffy coats, multiple urine fractions (buffered, un-processed, pelleted), semen, buccal cells, and serum samples. Archival collections are stored in high capacity, vapor phase liquid nitrogen cryogenic units as a part of the Johns Hopkins "Greening the Lab" initiative for energy efficiency.
Our efforts since the establishment of JHBUI Biorepository in 1994, has led to over 350 individual requests from academic and industrial collaborators. These collaborations have utilized over 12,300 individual aliquots, some of which were utilized in the following FDA clinical trials: cPSA, %fPSA, PCA3 and PHI (-2pPSA). We look forward to continued growth, enhancements to the collections and utilization so that we can continue to make great efforts in the detection and treatment of all urological cancers.